Is atomoxetine effective in some comorbid mental disorders in ADHD?

Abstract

Attention-Deficit/Hyperactivity Disorder (ADHD) is connected with high level of psychiatric comorbidity in paediatric population. Depressive disorder is common comorbid disorder co-existing with ADHD. Atomoxetine is worldwide approved for treatment of ADHD in paediatric population; in addition atomoxetine is effective and safe in treatment of some comorbid disorders in ADHD. Pharmacotherapy of depression is limited and residual symptoms are common. Fluoxetine is currently considered to be the gold standard of treatment of depression, but effectiveness of acute phase of treatment is not sufficient. Atomoxetine as a selective noradrenaline reuptake inhibitor or olanzapine as a multi receptors antagonist drug in combination with fluoxetine could be perspective augmented treatment strategy of depression just for their antidepressant effect. The aim of our following study is to evaluate and compare effectiveness and safety of monotherapy and combined/augmented therapy in acute phase of depression treatment in adolescence, as well as introduce complex modern research methodology of effectiveness and safety of treatment.

Detection of atomoxetine and its metabolites in the urine by thin-layer chromatography and mass spectrometry

“…The therapeutic daily dose is 40 mg daily increased to 80 mg after 3 days and up to 100 mg after 2 to 4 weeks [3]. Atomoxetine has also been shown to be effective for treating therapeutically resistant depression [4,5]. It can cause a range of side effects [2,[6][7][8], and episodes of acute and lethal atomoxetine poisoning also were registered [3,[9][10][11].…”

Editorial

“…Thus, this special issue of the European Pharmaceutical Journal represents a group of selected studies performed in the pharmacological institutes in Slovakia. For instance, two articles from Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava [1,2], provide some view on perspectives of the psychopharmacotherapy research in Slovakia, in particularly on the treatment of Attention-deficit/hyperactivity disorder (ADHD) and depression. In an another study performed in the Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, the authors have investigated the efficacy of trolox, carnosine, and its derivative trolox-carnosine administration in rats [3].…”